- Home
- PSTV vs EDSA Comparison
PSTV vs EDSA Comparison
Compare PSTV & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- EDSA
- Stock Information
- Founded
- PSTV 1996
- EDSA 2015
- Country
- PSTV United States
- EDSA Canada
- Employees
- PSTV N/A
- EDSA N/A
- Industry
- PSTV Medical/Dental Instruments
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- EDSA Health Care
- Exchange
- PSTV Nasdaq
- EDSA Nasdaq
- Market Cap
- PSTV 17.0M
- EDSA 15.4M
- IPO Year
- PSTV N/A
- EDSA N/A
- Fundamental
- Price
- PSTV $0.45
- EDSA $2.45
- Analyst Decision
- PSTV Strong Buy
- EDSA Strong Buy
- Analyst Count
- PSTV 4
- EDSA 2
- Target Price
- PSTV $7.88
- EDSA $13.00
- AVG Volume (30 Days)
- PSTV 8.4M
- EDSA 20.7K
- Earning Date
- PSTV 08-14-2025
- EDSA 08-08-2025
- Dividend Yield
- PSTV N/A
- EDSA N/A
- EPS Growth
- PSTV N/A
- EDSA N/A
- EPS
- PSTV N/A
- EDSA N/A
- Revenue
- PSTV $5,317,000.00
- EDSA N/A
- Revenue This Year
- PSTV $2.95
- EDSA N/A
- Revenue Next Year
- PSTV $7.89
- EDSA N/A
- P/E Ratio
- PSTV N/A
- EDSA N/A
- Revenue Growth
- PSTV N/A
- EDSA N/A
- 52 Week Low
- PSTV $0.16
- EDSA $1.55
- 52 Week High
- PSTV $2.31
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- PSTV 43.79
- EDSA 63.04
- Support Level
- PSTV $0.39
- EDSA $2.26
- Resistance Level
- PSTV $0.54
- EDSA $2.51
- Average True Range (ATR)
- PSTV 0.05
- EDSA 0.12
- MACD
- PSTV -0.02
- EDSA 0.01
- Stochastic Oscillator
- PSTV 22.96
- EDSA 69.70
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.